Viviana Frantellizzi*, Mariano Pontico, Arianna Pani, Roberto Pani and Giuseppe De Vincentis Pages 159 - 163 ( 5 )
Background: To our knowledge, no previous study or literature review has been performed about the effects of the extravasation of therapeutic radiopharmaceutical agents and its potential consequences, especially regarding alpha-particle emitting radiopharmaceuticals.
Methods: Even if Radium-223 dichloride is known to be a relatively safe drug to manage, despite the correctness of the procedures applied , unexpected delayed adverse effects can occur.
In our vast experience, we rarely observed lymphedema, even after some time, at the site of administration.
Results: Management of lymphedema caused by radiopharmaceuticals administration has been addressed through clinical examples. The sudden intervention allowed a fast remission of the signs and symptoms complained by patients treated with Radium-223 dichloride.
Conclusion: The management of adverse effects after radiopharmaceuticals administration as in case of lymphedema onset, is extremely simple. These data confirm the safety of Radium-223 treatment.
Ra-223 dichloride, alpha particle therapy, lymphedema, life quality, radiopharmaceutical adverse effects.
Department of Molecular Medicine, Sapienza University of Rome, Rome, Ph.D. Program in Morphogenesis and Tissue Engineering, Sapienza University of Rome, Rome, Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan “Statale”, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Rome